Pfizer obesity injection shows 12% weight loss in mid‑stage trial

Patients in Pfizer’s phase‑two trial lost up to 12.3% of body weight after switching to a once‑monthly injection, a result that could broaden the obesity‑drug market beyond weekly GLP‑1 shots [3].

Trial results and dosing schedule

The study began with patients receiving weekly injections for 12 weeks before moving to a monthly regimen. At week 28, participants on the monthly dose achieved an average weight reduction of 12.3% compared with placebo, and 10.5% when all patients—including those who discontinued—were considered [3]. No plateau was observed after the switch, suggesting continued loss through week 64, the trial’s planned endpoint.

Competitive landscape and market implications

Pfizer’s injection, identified as PF'3944, is an ultra‑long‑acting GLP‑1 analogue designed to stay active longer than existing weekly products such as Novo Nordisk’s Wegovy. The company positions the monthly format as a convenience alternative for patients who find weekly refrigeration or travel challenging [3]. While analysts note that patients already on injectable GLP‑1s may not migrate to daily oral pills, Pfizer argues that offering both weekly and monthly options could capture a broader segment of the obesity market [3].

Next steps and regulatory outlook

Pfizer plans to advance ten phase‑three trials for the monthly formulation later this year, with a higher dose projected to deliver up to 16% weight loss at week 28, according to internal modeling [3]. The company’s chief scientific officer highlighted the potential for the higher‑dose regimen to be “maybe best in class,” though no regulatory timeline has been disclosed.

What to watch

• Phase‑three trial launches – Pfizer aims to start ten late‑stage studies this year; trial outcomes will shape market expectations.
• Regulatory filings – FDA submission dates for the monthly GLP‑1 injection will indicate the timeline for potential approval.
• Pricing signals – Pfizer’s pricing strategy relative to weekly competitors could affect adoption once the product reaches market.

The trial’s early weight‑loss figures underscore a shift toward less frequent dosing in the obesity‑treatment space, raising questions about how quickly the market will accept a monthly GLP‑1 injection and whether it can carve out meaningful share from entrenched weekly products.